Abbott bets on cancer screening with $23 billion Exact Sciences deal

Abbott will buy cancer-test maker Exact Sciences for $105 a share in cash, valuing Exact at about $21 billion equity and up to $23 billion including roughly $1.8 billion of net debt, marking Abbott’s largest acquisition in nearly a decade and its first major move into cancer screening. The deal adds Exact’s Cologuard colorectal screen and Oncotype DX breast-cancer test to Abbott’s diagnostics portfolio, is expected to lift Exact revenue to more than $3 billion this year and Abbott’s diagnostics sales to over $12 billion, will be dilutive to adjusted EPS through 2027, and is slated to close in Q2 2026. Exact shares jumped about 18% premarket while Abbott slipped, and analysts warned the ~22% premium could pressure Abbott’s shares and multiples and questioned the strategic fit given Abbott lacks an oncology business.

Analysis

Abbott announced a cash acquisition of Exact Sciences at $105 per share, valuing Exact's equity at about $21 billion and the transaction at up to $23 billion including roughly $1.8 billion of net debt; the deal is characterized as Abbott's largest acquisition in nearly a decade and its first major entry into cancer screening by adding Cologuard and Oncotype DX to its diagnostics portfolio. The purchase price implies a near 22% premium to Exact's last close; Exact shares rose more than 18% to $102.1 in premarket trading while Abbott's shares slipped about 1%. Exact is projected to generate more than $3 billion in revenue this year with high‑teens organic growth, which would increase Abbott's diagnostics sales to over $12 billion annually. Abbott disclosed the transaction will be dilutive to adjusted EPS through 2027 and the deal is expected to close in Q2 2026 pending shareholder approval. Analysts, notably Bernstein's Christian Moore, flagged concerns over strategic fit given Abbott's lack of an oncology franchise and warned the premium could pressure Abbott's earnings multiples, highlighting integration and execution risks that could affect near‑term shareholder returns.

Key Decisions for Investors

• For Abbott holders: consider reducing exposure or maintaining a cautious hold until management provides post‑deal guidance on integration costs and EPS trajectory given stated dilution through 2027
• For Exact holders and event‑driven traders: the cash offer represents an immediate ~22% premium; evaluate taking gains versus holding through shareholder approval and the closing process targeted for Q2 2026
• For merger‑arbitrage or opportunistic investors: assess closing risk and integration uncertainty before initiating positions; the market is pricing near‑term dilution and strategic questions into Abbott shares
• For healthcare/diagnostics investors: monitor Actual revenue contribution from Cologuard and Oncotype DX to Abbott's diagnostics (> $12 billion target) and reprice exposure to companies tied to cancer‑screening secular growth